 | • レポートコード：MRC2302A006P • 出版社/出版日：360iResearch / 2023年2月1日 • レポート形態：英語、PDF、249ページ • 納品方法：Eメール（受注後3日） • 産業分類：医薬品 |
| Single User（1名利用、印刷可） | ￥742,350 (USD4,949) | ▷ お問い合わせ |
| Enterprise License（企業利用、印刷可） | ￥1,492,350 (USD9,949) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 360iResearch社発行の当調査レポートでは、2021年に1,037.21百万ドルであった世界のアレルギー用ワクチン市場規模が、2022年に1,153.72百万ドルに達し、2027年には1,983.40百万ドルまで年平均11.40%で成長すると予測しています。当レポートは、アレルギー用ワクチンの世界市場について調査し、序論、調査方法、エグゼクティブサマリー、市場概要、市場インサイト、アレルギー種類別（アレルギー性喘息、猫のふけアレルギー、草木花粉過敏症、ピーナッツ過敏症、その他）分析、ワクチン種類別（猫アレルギー用ワクチン、ハウスダストマイトアレルギーワクチン、注射用MPLアレルギーワクチン、ピーナツアレルギーワクチン、その他）分析、用途別（HIV、腫瘍、呼吸器）分析、エンドユーザー別（家庭、病院、専門クリニック）分析、地域別（南北アメリカ、アメリカ、カナダ、ブラジル、アジア太平洋、日本、中国、インド、韓国、台湾、ヨーロッパ/中東/アフリカ、イギリス、ドイツ、フランス、ロシア、その他）分析、競争状況など、以下の構成でまとめております。なお、当書には、Aimmue Therapeutics, Inc、Alexion Pharmaceuticals、ALK Abelló A/S、Allergy Therapeutics Plc、Allertein Therapeutics、Anergis SA、Angany Inc、Aravax、Astellas Pharma Inc.、Biomay AG、Capnia, Inc、Circassia Pharmaceuticals、Cytos Biotechnology AG、DBV Technologies SA、Ensi Pharama、fisher scientificなどの企業情報が含まれています。 ・序論 ・調査方法 ・エグゼクティブサマリー ・市場概要 ・市場インサイト ・世界のアレルギー用ワクチン市場規模：アレルギー種類別 - アレルギー性喘息の市場規模 - 猫のふけアレルギーの市場規模 - 草木花粉過敏症の市場規模 - ピーナッツ過敏症の市場規模 - その他アレルギー種類の市場規模 ・世界のアレルギー用ワクチン市場規模：ワクチン種類別 - 猫アレルギー用ワクチン市場規模 - ハウスダストマイトアレルギーワクチン市場規模 - 注射用MPLアレルギーワクチン市場規模 - ピーナツアレルギーワクチン市場規模 - その他ワクチン種類市場規模 ・世界のアレルギー用ワクチン市場規模：用途別 - HIVにおける市場規模 - 腫瘍における市場規模 - 呼吸器における市場規模 ・世界のアレルギー用ワクチン市場規模：エンドユーザー別 - 家庭における市場規模 - 病院における市場規模 - 専門クリニックにおける市場規模 ・世界のアレルギー用ワクチン市場規模：地域別 - 南北アメリカのアレルギー用ワクチン市場規模 アメリカのアレルギー用ワクチン市場規模 カナダのアレルギー用ワクチン市場規模 ブラジルのアレルギー用ワクチン市場規模 ... - アジア太平洋のアレルギー用ワクチン市場規模 日本のアレルギー用ワクチン市場規模 中国のアレルギー用ワクチン市場規模 インドのアレルギー用ワクチン市場規模 韓国のアレルギー用ワクチン市場規模 台湾のアレルギー用ワクチン市場規模 ... - ヨーロッパ/中東/アフリカのアレルギー用ワクチン市場規模 イギリスのアレルギー用ワクチン市場規模 ドイツのアレルギー用ワクチン市場規模 インドのアレルギー用ワクチン市場規模 フランスのアレルギー用ワクチン市場規模 ロシアのアレルギー用ワクチン市場規模 ... - その他地域のアレルギー用ワクチン市場規模 ・競争状況 ・企業情報 |
The Global Allergy Vaccine Market size was estimated at USD 1,037.21 million in 2021 and expected to reach USD 1,153.72 million in 2022, and is projected to grow at a CAGR 11.40% to reach USD 1,983.40 million by 2027.
Market Statistics:
The report provides market sizing and forecast across 7 major currencies – USD, EUR, JPY, GBP, AUD, CAD, and CHF. It helps organization leaders make better decisions when currency exchange data is readily available. In this report, the years 2018 and 2020 are considered as historical years, 2021 as the base year, 2022 as the estimated year, and years from 2023 to 2027 are considered as the forecast period.
Market Segmentation & Coverage:
This research report categorizes the Allergy Vaccine to forecast the revenues and analyze the trends in each of the following sub-markets:
Based on Allergy Type, the market was studied across Allergic Asthma, Cat Dander Allergy, Grass Pollen Hypersensitivity, Peanut Hypersensitivity, Seasonal Allergic Rhinitis, and Tree Pollen Hypersensitivity.
Based on Vaccine Type, the market was studied across Cat Allergy Vaccine, House Dust Mite Allergy Vaccine, Injectable MPL Allergy Vaccine, Peanut Allergy Vaccine, and Ragweed Allergy Immunotherapy Vaccine.
Based on Application, the market was studied across HIV, Oncology, and Respiratory.
Based on End User, the market was studied across Homecare, Hospitals, and Specialty Clinics.
Based on Region, the market was studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.
Cumulative Impact of COVID-19:
COVID-19 is an incomparable global public health emergency that has affected almost every industry, and the long-term effects are projected to impact the industry growth during the forecast period. Our ongoing research amplifies our research framework to ensure the inclusion of underlying COVID-19 issues and potential paths forward. The report delivers insights on COVID-19 considering the changes in consumer behavior and demand, purchasing patterns, re-routing of the supply chain, dynamics of current market forces, and the significant interventions of governments. The updated study provides insights, analysis, estimations, and forecasts, considering the COVID-19 impact on the market.
Cumulative Impact of 2022 Russia Ukraine Conflict:
We continuously monitor and update reports on political and economic uncertainty due to the Russian invasion of Ukraine. Negative impacts are significantly foreseen globally, especially across Eastern Europe, European Union, Eastern & Central Asia, and the United States. This contention has severely affected lives and livelihoods and represents far-reaching disruptions in trade dynamics. The potential effects of ongoing war and uncertainty in Eastern Europe are expected to have an adverse impact on the world economy, with especially long-term harsh effects on Russia.This report uncovers the impact of demand & supply, pricing variants, strategic uptake of vendors, and recommendations for Allergy Vaccine market considering the current update on the conflict and its global response.
Competitive Strategic Window:
The Competitive Strategic Window analyses the competitive landscape in terms of markets, applications, and geographies to help the vendor define an alignment or fit between their capabilities and opportunities for future growth prospects. It describes the optimal or favorable fit for the vendors to adopt successive merger and acquisition strategies, geography expansion, research & development, and new product introduction strategies to execute further business expansion and growth during a forecast period.
FPNV Positioning Matrix:
The FPNV Positioning Matrix evaluates and categorizes the vendors in the Allergy Vaccine Market based on Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) that aids businesses in better decision making and understanding the competitive landscape.
Market Share Analysis:
The Market Share Analysis offers the analysis of vendors considering their contribution to the overall market. It provides the idea of its revenue generation into the overall market compared to other vendors in the space. It provides insights into how vendors are performing in terms of revenue generation and customer base compared to others. Knowing market share offers an idea of the size and competitiveness of the vendors for the base year. It reveals the market characteristics in terms of accumulation, fragmentation, dominance, and amalgamation traits.
Competitive Scenario:
The Competitive Scenario provides an outlook analysis of the various business growth strategies adopted by the vendors. The news covered in this section deliver valuable thoughts at the different stage while keeping up-to-date with the business and engage stakeholders in the economic debate. The competitive scenario represents press releases or news of the companies categorized into Merger & Acquisition, Agreement, Collaboration, & Partnership, New Product Launch & Enhancement, Investment & Funding, and Award, Recognition, & Expansion. All the news collected help vendor to understand the gaps in the marketplace and competitor’s strength and weakness thereby, providing insights to enhance product and service.
Company Usability Profiles:
The report profoundly explores the recent significant developments by the leading vendors and innovation profiles in the Global Allergy Vaccine Market, including Aimmue Therapeutics, Inc, Alexion Pharmaceuticals, ALK Abelló A/S, Allergy Therapeutics Plc, Allertein Therapeutics, Anergis SA, Angany Inc, Aravax, Astellas Pharma Inc., Biomay AG, Capnia, Inc, Circassia Pharmaceuticals, Cytos Biotechnology AG, DBV Technologies SA, Ensi Pharama, fisher scientific, HAL Allergy Group, Immunomic Therapeutics, Inc., Jubilant Pharma N.V., LETI Pharma, Merck & Co., Inc., Novartis International AG, Sementis Ltd, Stallergenes Greer plc., and Zicam LLC.
The report provides insights on the following pointers:
1. Market Penetration: Provides comprehensive information on the market offered by the key players
2. Market Development: Provides in-depth information about lucrative emerging markets and analyze penetration across mature segments of the markets
3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments
4. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players
5. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments
The report answers questions such as:
1. What is the market size and forecast of the Global Allergy Vaccine Market?
2. What are the inhibiting factors and impact of COVID-19 shaping the Global Allergy Vaccine Market during the forecast period?
3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Allergy Vaccine Market?
4. What is the competitive strategic window for opportunities in the Global Allergy Vaccine Market?
5. What are the technology trends and regulatory frameworks in the Global Allergy Vaccine Market?
6. What is the market share of the leading vendors in the Global Allergy Vaccine Market?
7. What modes and strategic moves are considered suitable for entering the Global Allergy Vaccine Market?
1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Increasing prevalence of allergies globally
5.1.1.2. Increasing air pollution with industrialization coupled with growing tobacco consumption
5.1.1.3. Rising awareness among consumers about the allergies
5.1.2. Restraints
5.1.2.1. Limited allergy vaccine manufacturers
5.1.3. Opportunities
5.1.3.1. Research and development for the production of specific allergy vaccine
5.1.3.2. Government and private sector initiatives in the production of vaccines
5.1.4. Challenges
5.1.4.1. Capital intensive in the production of allergy vaccines
5.2. Cumulative Impact of COVID-19
6. Allergy Vaccine Market, by Allergy Type
6.1. Introduction
6.2. Allergic Asthma
6.3. Cat Dander Allergy
6.4. Grass Pollen Hypersensitivity
6.5. Peanut Hypersensitivity
6.6. Seasonal Allergic Rhinitis
6.7. Tree Pollen Hypersensitivity
7. Allergy Vaccine Market, by Vaccine Type
7.1. Introduction
7.2. Cat Allergy Vaccine
7.3. House Dust Mite Allergy Vaccine
7.4. Injectable MPL Allergy Vaccine
7.5. Peanut Allergy Vaccine
7.6. Ragweed Allergy Immunotherapy Vaccine
8. Allergy Vaccine Market, by Application
8.1. Introduction
8.2. HIV
8.3. Oncology
8.4. Respiratory
9. Allergy Vaccine Market, by End User
9.1. Introduction
9.2. Homecare
9.3. Hospitals
9.4. Specialty Clinics
10. Americas Allergy Vaccine Market
10.1. Introduction
10.2. Argentina
10.3. Brazil
10.4. Canada
10.5. Mexico
10.6. United States
11. Asia-Pacific Allergy Vaccine Market
11.1. Introduction
11.2. Australia
11.3. China
11.4. India
11.5. Indonesia
11.6. Japan
11.7. Malaysia
11.8. Philippines
11.9. Singapore
11.10. South Korea
11.11. Taiwan
11.12. Thailand
11.13. Vietnam
12. Europe, Middle East & Africa Allergy Vaccine Market
12.1. Introduction
12.2. Denmark
12.3. Egypt
12.4. Finland
12.5. France
12.6. Germany
12.7. Israel
12.8. Italy
12.9. Netherlands
12.10. Nigeria
12.11. Norway
12.12. Poland
12.13. Qatar
12.14. Russia
12.15. Saudi Arabia
12.16. South Africa
12.17. Spain
12.18. Sweden
12.19. Switzerland
12.20. Turkey
12.21. United Arab Emirates
12.22. United Kingdom
13. Competitive Landscape
13.1. FPNV Positioning Matrix
13.1.1. Quadrants
13.1.2. Business Strategy
13.1.3. Product Satisfaction
13.2. Market Ranking Analysis, By Key Player
13.3. Market Share Analysis, By Key Player
13.4. Competitive Scenario
13.4.1. Merger & Acquisition
13.4.2. Agreement, Collaboration, & Partnership
13.4.3. New Product Launch & Enhancement
13.4.4. Investment & Funding
13.4.5. Award, Recognition, & Expansion
14. Company Usability Profiles
14.1. Aimmue Therapeutics, Inc
14.1.1. Business Overview
14.1.2. Key Executives
14.1.3. Product & Services
14.2. Alexion Pharmaceuticals
14.2.1. Business Overview
14.2.2. Key Executives
14.2.3. Product & Services
14.3. ALK Abelló A/S
14.3.1. Business Overview
14.3.2. Key Executives
14.3.3. Product & Services
14.4. Allergy Therapeutics Plc
14.4.1. Business Overview
14.4.2. Key Executives
14.4.3. Product & Services
14.5. Allertein Therapeutics
14.5.1. Business Overview
14.5.2. Key Executives
14.5.3. Product & Services
14.6. Anergis SA
14.6.1. Business Overview
14.6.2. Key Executives
14.6.3. Product & Services
14.7. Angany Inc
14.7.1. Business Overview
14.7.2. Key Executives
14.7.3. Product & Services
14.8. Aravax
14.8.1. Business Overview
14.8.2. Key Executives
14.8.3. Product & Services
14.9. Astellas Pharma Inc.
14.9.1. Business Overview
14.9.2. Key Executives
14.9.3. Product & Services
14.10. Biomay AG
14.10.1. Business Overview
14.10.2. Key Executives
14.10.3. Product & Services
14.11. Capnia, Inc
14.11.1. Business Overview
14.11.2. Key Executives
14.11.3. Product & Services
14.12. Circassia Pharmaceuticals
14.12.1. Business Overview
14.12.2. Key Executives
14.12.3. Product & Services
14.13. Cytos Biotechnology AG
14.13.1. Business Overview
14.13.2. Key Executives
14.13.3. Product & Services
14.14. DBV Technologies SA
14.14.1. Business Overview
14.14.2. Key Executives
14.14.3. Product & Services
14.15. Ensi Pharama
14.15.1. Business Overview
14.15.2. Key Executives
14.15.3. Product & Services
14.16. fisher scientific
14.16.1. Business Overview
14.16.2. Key Executives
14.16.3. Product & Services
14.17. HAL Allergy Group
14.17.1. Business Overview
14.17.2. Key Executives
14.17.3. Product & Services
14.18. Immunomic Therapeutics, Inc.
14.18.1. Business Overview
14.18.2. Key Executives
14.18.3. Product & Services
14.19. Jubilant Pharma N.V.
14.19.1. Business Overview
14.19.2. Key Executives
14.19.3. Product & Services
14.20. LETI Pharma
14.20.1. Business Overview
14.20.2. Key Executives
14.20.3. Product & Services
14.21. Merck & Co., Inc.
14.21.1. Business Overview
14.21.2. Key Executives
14.21.3. Product & Services
14.22. Novartis International AG
14.22.1. Business Overview
14.22.2. Key Executives
14.22.3. Product & Services
14.23. Sementis Ltd
14.23.1. Business Overview
14.23.2. Key Executives
14.23.3. Product & Services
14.24. Stallergenes Greer plc.
14.24.1. Business Overview
14.24.2. Key Executives
14.24.3. Product & Services
14.25. Zicam LLC
14.25.1. Business Overview
14.25.2. Key Executives
14.25.3. Product & Services
15. Appendix
15.1. Discussion Guide
15.2. License & Pricing